An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer

Update Il y a 5 ans
Reference: EUCTR2007-001128-11

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To compare Invasive Disease-Free Survival (IDFS) of patients randomised to treatment with adjuvant chemotherapy alone or to adjuvant chemotherapy with 1 year of bevacizumab.


Inclusion criteria

  • Early primary invasive adenocarcinoma of the breast (triple negative and/or basal-like phenotype)